Clinical trials: Pseudomonas
Cystic Fibrosis
Aztreonam Lysine for Pseudomonas Infection Eradication Study
This is an open-label, multi-center study in pediatric patients age 3 months to less than 18 years with cystic fibrosis (CF) and newly detected Pseudomonas aeruginosa (PA) pulmonary colonization/infection.
- Trial name
- ALPINE (NCT01375049)
- Testing
- Aztreonam for Inhalation Solution (AZLI)
- Where
- 58 sites in United States, Austria and 7 more
- Volunteers
- 105 people
- Sponsor
- Gilead Sciences
Surgical Procedure, Unspecified
Reducing ESKAPE Transmission in the Operating Room
This study is designed to examine the impact of a personalized, body worn alcohol dispenser on the epidemiology of ESKAPE transmission in the anesthesia work area for patients undergoing surgery requiring general anesthesia.
- Trial name
- NCT06274918
- Testing
- Personalized Body-Worn Alcohol Dispenser
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Cystic Fibrosis, Infection
Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis
Hypothesis: Daily gargling with specific avian antibodies against Pseudomonas aeruginosa will prevent infections with this bacteria in patients with Cystic fibrosis (CF).
- Conditions
- Cystic Fibrosis, Infection, Pseudomonas Aeruginosa
- Trial name
- PseudIgY (NCT00633191)
- Testing
- Anti-pseudomonas IgY gargle
- Where
- Sweden
- Volunteers
- 14 people
- Sponsor
- Immunsystem AB
Bloodstream Infection
Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia
Phase IV, open-labeled, randomized and multicenter clinical trial to demonstrate the superiority of antibiotics with authorized indication for 7 days versus 14 days in the treatment of bloodstream infections produced by P.
- Trial name
- SHORTEN2 (NCT05210439)
- Testing
- Short-treatment of any active antibiotic regimen, Long-treatment of any active antibiotic regimen
- Where
- 37 sites in Spain
- Volunteers
- 306 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Bronchiectasis
Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa
It is acknowledged that IL-18, as a product of the inflammasome, is involved in host defence against viral and bacterial stimuli by modulating the immune response.
- Trial name
- NCT02491723
- Testing
- Azithromycin
- Where
- China
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Jin-Fu Xu
BRONCHIECTASIS
Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa
Statins are a class of drug used to prevent heart attacks and strokes by lowering blood cholesterol levels. They have also been found to have a beneficial "side effect" of lowering the level of inflammation in the body.
- Trial name
- NCT01299194
- Testing
- ATORVASTATIN
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University of Edinburgh
Infection in ICU, Sepsis
Early Optimization of Ceftazidime Regimen in Critical Care
Hospital-acquired infections, most of which are caused by Gram-negative bacteria, are common in intensive care units and have a major impact on patient prognosis.
- Conditions
- Infection in ICU, Sepsis, Septic Shock, Pseudomonas Aeruginosa Infection
- Trial name
- FORTOPTIM_1 (NCT07085624)
- Testing
- ceftazidime, plasma ceftazidime dosage
- Where
- 8 sites in France
- Volunteers
- 128 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa
Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection
The use of inhaled medications for the treatment of pulmonary diseases allows for the delivery of a high concentration of a drug at the site of disease with reduced systemic absorption and risk of systemic adverse effects.
- Trial name
- TOBI (NCT02102152)
- Testing
- Tobramycin
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rabin Medical Center
Pseudomonas Aeruginosa
Pathobiomes in Gut of Critically Ill Patients
Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain…
- Trial name
- NCT06822465
- Testing
- P. aeruginosa using in vitro and in vivo assays
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Osteomyelitis, Pseudomonas Infections
Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa
This study looks at how well one antibiotic (monotherapy) works compared to two antibiotics (combination therapy) in treating bone infections caused by Pseudomonas aeruginosa.
- Conditions
- Osteomyelitis, Pseudomonas Infections, Pseudomonas Aeruginosa, Bacterial Infections
- Trial name
- NCT07056881
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier de Saint-Denis
Rapid Detection, Pseudomonas Aeruginosa Infection
Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection
The aim of this study is to observe specimens of bronchoalveolar lavage fluid from patients using a reflection enhanced dark-field scattering microscopy.
- Trial name
- NCT06986512
- Testing
- bronchoscopy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation
A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis
The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis.
- Conditions
- Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation, Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa, Viral Infection
- Trial name
- BARRIER (NCT06931002)
- Testing
- Rhinovirus A-16 Infection
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Imperial College London
COPD, Respiratory Tract Infections
Targeted AntiBiotics for Chronic Pulmonary Diseases
This is a prospective, randomized multi-center trial investigating the impact of lower airway infection with P. aeruginosa in COPD patients. The aim of the study is to evaluate if targeted antibiotic therapy against P.
- Conditions
- COPD, Respiratory Tract Infections, Pseudomonas Aeruginosa, Bronchiectasis
- Trial name
- Target-ABC (NCT03262142)
- Testing
- Piperacillin/tazobactam, Ciprofloxacin
- Where
- Denmark
- Volunteers
- 51 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Leukemia, Hairy Cell
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Background: Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells.
- Trial name
- NCT01829711
- Testing
- Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox
- Where
- 34 sites in United States, Belgium and 12 more
- Volunteers
- 80 people
- Sponsor
- MedImmune LLC
Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
Antimicrobial resistance is a major global problem, particularly in hospital-acquired infections (HAIs). Gram-negative bacilli (GNB), including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, are among the…
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection, Severe Infection, Pseudomonas Aeruginosa
- Trial name
- OPTIMISE (NCT05210387)
- Testing
- Duration of therapy
- Where
- 29 sites in Brazil
- Volunteers
- 107 people
- Sponsor
- Hospital Moinhos de Vento
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Study With Phage for CF Subjects With Pseudomonas Lung Infection
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects.
- Trial name
- NCT06998043
- Testing
- BX004
- Where
- 14 sites in United States
- Volunteers
- 63 people
- Sponsor
- BiomX Ltd
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Pseudomonas Aeruginosa Pneumonia
Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
Prospective, double-blind, randomized assessment of the efficacy, safety and pharmacokinetic of Aerucin® as adjunct treatment (in addition to standard of care antibiotics) for pneumonia caused by P. aeruginosa.
- Trial name
- NCT03027609
- Testing
- AR-105
- Where
- 111 sites in United States, Australia and 15 more
- Volunteers
- 158 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
Peritoneal Dialysis-related Infection
Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related Infection
Peritoneal dialysis-related infection is a complication that leads to peritoneal dialysis catheter removal or patient death. The present study aimed to investigate peritoneal dialysis-related infection, causative pathogens…
- Trial name
- NCT05251584
- Testing
- Mupirocin, Gentamicin
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Pseudomonas Infection
Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects
The objective is to determine the safety, tolerability and pharmacokinetics (PK) of 2 single doses of ZTI-01 (1g and 8g infused over 1-hr) and a single dose of the Reference Label Drug, Monurol® (oral sachet, 3g).
- Trial name
- NCT02178254
- Testing
- Fosfomycin tromethamine, Fosfomycin disodium
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)